Pinnacle Biologics, Inc. and INTERmedic announced a global manufacturing and distribution agreement of INTERmedic's latest photodynamic therapy (PDT) laser for exclusive use with Pinnacle's PHOTOFRIN (R) (porfimer sodium) for injection. PDT is a two-step process, which uses a photosensitizing drug activated inside the body by laser light to kill cells. The agreement creates a customized PDT application combining PHOTOFRIN, a photoactivated agent, with INTERmedic's newest endoscopic laser delivery device. The device is already approved in Europe. Pinnacle anticipates registration in the United States and other global markets within the next 12-18 months. PDT for cancer is an advanced therapeutic approach that needs to be expanded and further developed.

Pinnacle Biologics, Inc. announced that the Board of Directors has elected Robert S. Altman, Ph.D. as Chief Commercial Officer, effective immediately. Mr. Altman is a proven leader with over 20 years experience in pharmaceutical industry. He was most recently CEO and President of Marathon Pharmaceuticals, LLC. From 2004 to 2007 Bob served as Senior Vice President Marketing and Sales of Astellas Pharma US. Previously Mr. Altman worked at Abbott Laboratories for sixteen years in a variety of positions rising to VP General Manager. The Board of Directors of company also elected Sharon Ayd, Ph.D. as Chief Scientific Officer, effective immediately. Sharon has recently been consulting with Pinnacle leading the Regulatory, Quality and Scientific Affairs team. She has a breadth of pharmaceutical experience in entrepreneurial minded organizations. Most recently Sharon was VP, Global R&D operations for the One 2 One business unit at Hospira Inc. Previously she held a number of operating and senior management positions at start-up biopharmaceutical companies.

Pinnacle Biologics, Inc. announce the appointment of Bioprojet Pharma SARL, effective March 15, 2012, as its exclusive distributor for ETHYOL (amifostine) and PHOTOFRIN (Porfimer Sodium) in select European countries. Ethyol is a cytoprotective agent indicated to reduce the incidence of moderate to severe xerostomia (dry mouth) following radiation treatment for head and neck cancer and to reduce cumulative renal toxicity associated with repeated administration of cisplatin in patients with ovarian cancer. Bioprojet has rights to distribute Ethyol in France, Italy, Spain, Germany, the Benelux and other countries in the Pinnacle territory where the product is approved by the regulatory authorities. Photofrin is a photo-activated drug and is indicated for the treatment of thoracic malignancies, specifically non-small cell lung cancer and esophageal cancer. Bioprojet has rights to distribute the product initially in France, Germany and the United Kingdom.